Dr. Reddy’s Says It Faces U.S. Scrutiny Over Packaging Rules

  • Stock falls more than 2 percent after commission sends letter
  • Company says it complied with rules and will defend itself

Dr. Reddy’s Laboratories Ltd. said a U.S. consumer safety watchdog has asked the nation’s Department of Justice to take action against India’s second-largest drugmaker for its alleged failure to comply with packaging and reporting rules.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.